Effect of CYP1A2, CYP2D6, and CYP3A4 Variation on Antipsychotic Treatment Outcomes

Guardado en:

Detalles Bibliográficos
Publicado en:	Pharmaceuticals vol. 18, no. 6 (2025), p. 892-919
Autor principal:	Varney, Lauren
Otros Autores:	Murtough, Stephen, Cotic Marius, Abidoph Rosemary, Chan, Lian, Saadullah Khani Noushin, Richards-Belle, Alvin, Richards-Brown, Maria, Mills, Daisy, Panconesi Daniele, Dawda Yogita, Sharma, Parveen, Shah, Chetan, Secchi Agostina, Nilforooshan Ramin, Mudholkar Santosh, Murdoch, Rosie, Molai Jazmin, Griffiths, Rebecca, Senthilkumar Suruthy, Blake, Helen, Lankshear, Steve, McRoberts, Jennifer, Pastor, Bethany, Carmel, Thomas, Richards, Sabrina, Welfare-Wilson, Alison, Sai-Bo, Cheung, Cox, Rebecca, Jibero, Anita Chinazam, Anad Reanne, Laczik Rebeka, Ghali Sharif, Berry, Alex J, Curwen, Joanna, Koye, Odutoye, Kottalgi Girija, Williams, Sally, Wong, Solomon, Anandan Nithya, Pius Georgy, Ajiteru Tonye, Clark, Victoria, van Driel Philip, Bashir Amir, Court, Samantha, Pawsey Minerva, Skowronska Anna, Woodley, Jessica, Bramon Elvira
Publicado:	MDPI AG
Materias:	Food & Drug Administration > FDA United Kingdom > UK Quality of life Schizophrenia Mental disorders Psychotropic drugs Psychosis Side effects Mental depression Licenses Bipolar disorder Metabolism Mental health Ethnicity Genes Enzymes Antipsychotics Clinical outcomes Drug dosages
Acceso en línea:	Citation/Abstract Full Text + Graphics Full Text - PDF
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!